Alterity Therapeutics, a biotechnology company, announced the presentation of three posters at the American Academy of Neurology (AAN) 2024 Annual Meeting, which took place from April 13-18 in Denver, Colorado. The presentations focused on the company's research in Parkinson’s disease and Multiple System Atrophy (MSA), including data from the ATH434-201 Phase 2 clinical trial. ATH434, Alterity's lead candidate, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration and has shown promise in preclinical studies. The Phase 2 trial data presented at AAN included baseline fluid biomarkers, neuroimaging, and clinical data from 65 participants with early-stage MSA. The trial aims to demonstrate the efficacy of ATH434 in modifying the disease by targeting labile cellular iron and α-synuclein aggregation. Additionally, the bioMUSE natural...Show More

Alterity Therapeutics, a biotechnology company, announced the presentation of three posters at the American Academy of Neurology (AAN) 2024 Annual Meeting, which took place from April 13-18 in Denver, Colorado. The presentations focused on the company's research in Parkinson’s disease and Multiple System Atrophy (MSA), including data from the ATH434-201 Phase 2 clinical trial. ATH434, Alterity's lead candidate, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration and has shown promise in preclinical studies. The Phase 2 trial data presented at AAN included baseline fluid biomarkers, neuroimaging, and clinical data from 65 participants with early-stage MSA. The trial aims to demonstrate the efficacy of ATH434 in modifying the disease by targeting labile cellular iron and α-synuclein aggregation. Additionally, the bioMUSE natural history study provided insights into the progression of MSA, with plasma Neurofilament Light Chain (NfL) levels emerging as a potential biomarker for disease progression. Alterity also reported on a primate study of Parkinson’s disease, where ATH434 treatment was associated with reduced motor impairment and abnormal iron levels in the brain. The company's ATH434 has received Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission and is currently being evaluated in two Phase 2 clinical trials.